ATX Stock Overview
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.086 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.055 |
| Beta | 0.84 |
| 1 Month Change | -2.27% |
| 3 Month Change | -44.52% |
| 1 Year Change | 6.17% |
| 3 Year Change | -47.88% |
| 5 Year Change | 28.36% |
| Change since IPO | -95.70% |
Recent News & Updates
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
Shareholder Returns
| ATX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 1.2% | 0.9% | -0.5% |
| 1Y | 6.2% | 3.7% | 8.2% |
Return vs Industry: ATX exceeded the Australian Biotechs industry which returned 3.7% over the past year.
Return vs Market: ATX underperformed the Australian Market which returned 8.2% over the past year.
Price Volatility
| ATX volatility | |
|---|---|
| ATX Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: ATX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ATX's weekly volatility has decreased from 17% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors.
Amplia Therapeutics Limited Fundamentals Summary
| ATX fundamental statistics | |
|---|---|
| Market cap | AU$29.80m |
| Earnings (TTM) | -AU$6.19m |
| Revenue (TTM) | AU$3.41m |
8.7x
P/S Ratio-4.8x
P/E RatioIs ATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATX income statement (TTM) | |
|---|---|
| Revenue | AU$3.41m |
| Cost of Revenue | AU$401.60k |
| Gross Profit | AU$3.01m |
| Other Expenses | AU$9.20m |
| Earnings | -AU$6.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 88.23% |
| Net Profit Margin | -181.41% |
| Debt/Equity Ratio | 0% |
How did ATX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 11:55 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amplia Therapeutics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|